Copyright Information of the Article Published Online

REFERENCES

1 Cárdenas A, Ginès P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care 2011; 17: 184-189 [PMID: 21311322 DOI: 10.1097/MCC.0b013e328344b3da]

2 Biancofiore G, Davis CL. Renal dysfunction in the perioperative liver transplant period. Curr Opin Organ Transplant 2008; 13: 291-297 [PMID: 18685320 DOI: 10.1097/MOT.0b013e328300a058]

3 Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5: 156-168 [PMID: 25133044 DOI: 10.4292/wjgpt.v5.i3.156]

4 Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol 2015; 2015: 108139 [PMID: 26266048 DOI: 10.1155/2015/108139]

5 McGuire BM, Julian BA, Bynon JS, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144: 735-741 [PMID: 16702589 DOI: 10.7326/0003-4819-144-10-200605160-00007]

6 Davis CL, Feng S, Sung R, Wong F, Goodrich NP, Melton LB, Reddy KR, Guidinger MK, Wilkinson A, Lake J. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7: 1702-1709 [PMID: 17532752 DOI: 10.1111/j.1600-6143.2007.01856.x]

7 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077 [PMID: 19003880 DOI: 10.1002/hep.22605]

8 Baraldi O, Valentini C, Donati G, Comai G, Cuna V, Capelli I, Angelini ML, Moretti MI, Angeletti A, Piscaglia F, La Manna G. Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol 2015; 4: 511-520 [PMID: 26558188 DOI: 10.5527/wjn.v4.i5.511]

9 Davenport A, Cholongitas E, Xirouchakis E, Burroughs AK. Pitfalls in assessing renal function in patients with cirrhosis--potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 2011; 26: 2735-2742 [PMID: 21690201 DOI: 10.1093/ndt/gfr354]

10 Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit 1983; 5: 161-168 [PMID: 6879639 DOI: 10.1097/00007691-198306000-00002]

11 Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52: 605-613 [PMID: 20185192 DOI: 10.1016/j.jhep.2009.11.025]

12 Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008; 300: 2371-2378 [PMID: 19033587 DOI: 10.1001/jama.2008.720]

13 Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med 1988; 39: 465-490 [PMID: 3285786 DOI: 10.1146/annurev.me.39.020188.002341]

14 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470 [PMID: 10075613 DOI: 10.7326/0003-4819-130-6-199903160-00002]

15 Sterner G, Frennby B, Mansson S, Nyman U, Van Westen D, Almén T. Determining ‘true’ glomerular filtration rate in healthy adults using infusion of inulin and comparing it with values obtained using other clearance techniques or prediction equations. Scand J Urol Nephrol 2008; 42: 278-285 [PMID: 17943640 DOI: 10.1080/00365590701701806]

16 Cruz DN, Bagshaw SM, Maisel A, Lewington A, Thadhani R, Chakravarthi R, Murray PT, Mehta RL, Chawla LS. Use of biomarkers to assess prognosis and guide management of patients with acute kidney injury. Contrib Nephrol 2013; 182: 45-64 [PMID: 23689655 DOI: 10.1159/000349965]

17 Qasem AA, Farag SE, Hamed E, Emara M, Bihery A, Pasha H. Urinary biomarkers of acute kidney injury in patients with liver cirrhosis. ISRN Nephrol 2014; 2014: 376795 [PMID: 24967242 DOI: 10.1155/2014/376795]

18 Aberg F, Lempinen M, Hollmén M, Nordin A, Mäkisalo H, Isoniemi H. Neutrophil gelatinase-associated lipocalin associated with irreversibility of pre-liver transplant kidney dysfunction. Clin Transplant 2014; 28: 869-876 [PMID: 24930480 DOI: 10.1111/ctr.12394]

19 Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57: 2362-2370 [PMID: 22562534 DOI: 10.1007/s10620-012-2180-x]

20 Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, Yeon JE, Byun KS, Kim CD, Ryu HS, Um SH. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009; 29: 1521-1527 [PMID: 19725889 DOI: 10.1111/j.1478-3231.2009.02105.x]

21 Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int 2011; 5: 927-933 [PMID: 21484118 DOI: 10.1007/s12072-011-9266-y]

22 Barbano B, Sardo L, Gigante A, Gasperini ML, Liberatori M, Giraldi GD, Lacanna A, Amoroso A, Cianci R. Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs. Curr Vasc Pharmacol 2014; 12: 125-135 [PMID: 24678726 DOI: 10.2174/157016111201140327163930]

23 Bataller R, Ginès P, Arroyo V, Rodés J. Hepatorenal syndrome. Clin Liver Dis 2000; 4: 487-507 [PMID: 11232202 DOI: 10.1016/S1089-3261(05)70120-3]

24 Mijac D, Kezić A, Stojimirović B. [Hepatorenal syndrome]. Srp Arh Celok Lek 2007; 135: 98-104 [PMID: 17503577]

25 Cárdenas A, Ginès P. Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 338-348 [PMID: 16741553 DOI: 10.1038/ncpgasthep0517]

26 Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, Rodés J, Ginès P. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282-1289 [PMID: 15834937 DOI: 10.1002/hep.20687]

27 Thomas ME, Blaine C, Dawnay A, Devonald MA, Ftouh S, Laing C, Latchem S, Lewington A, Milford DV, Ostermann M. The definition of acute kidney injury and its use in practice. Kidney Int 2015; 87: 62-73 [PMID: 25317932 DOI: 10.1038/ki.2014.328]

28 Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012; 18: 3035-3049 [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035]

29 Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, Graupera I, Ariza X, Pereira G, Alfaro I, Cárdenas A, Fernández J, Poch E, Ginès P. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 2013; 59: 474-481 [PMID: 23669284 DOI: 10.1016/j.jhep.2013.04.036]

30 Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, Morando F, Gola E, Frigo AC, Gatta A, Angeli P. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013; 59: 482-489 [PMID: 23665185 DOI: 10.1016/j.jhep.2013.03.039]

31 Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl 2012; 18: 539-548 [PMID: 22250075 DOI: 10.1002/lt.23384]

32 Junghare M, Ibrahim HN. Not all types of acute kidney injury are equal in the setting of liver transplantation. Liver Transpl 2012; 18: 507-508 [PMID: 22422672 DOI: 10.1002/lt.23428]

33 Russ KB, Stevens TM, Singal AK. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol 2015; 3: 195-204 [PMID: 26623266 DOI: 10.14218/jcth.2015.00015]

34 Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35: 1179-1185 [PMID: 11981768 DOI: 10.1053/jhep.2002.33160]

35 Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, Pereira G, Marinelli M, Pavesi M, Fernández J, Rodés J, Arroyo V, Ginès P. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-496.e4 [PMID: 20682324 DOI: 10.1053/j.gastro.2010.07.043]

36 Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827 [PMID: 14654322 DOI: 10.1016/s0140- 6736(03)14903-3]

37 Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68: 362-370 [PMID: 15954928 DOI: 10.1111/j.1523-1755.2005.00408.x]

38 EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]

39 Arroyo V, Fernández J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011; 7: 517-526 [PMID: 21826080 DOI: 10.1038/nrneph.2011.96]

40 Angeli P, Morando F, Cavallin M, Piano S. Hepatorenal syndrome. Contrib Nephrol 2011; 174: 46-55 [PMID: 21921608 DOI: 10.1159/ 000329235]

41 Cavallin M, Fasolato S, Marenco S, Piano S, Tonon M, Angeli P. The Treatment of Hepatorenal Syndrome. Dig Dis 2015; 33: 548-554 [PMID: 26159272 DOI: 10.1159/000375346]

42 Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A. Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepatogastroenterology 2003; 50 Suppl 2: ccciii-cccccv [PMID: 15244209]

43 Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology 2016; 63: 983-992 [PMID: 26659927 DOI: 10.1002/hep.28396]

44 Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011; 17: 1328-1332 [PMID: 21837734 DOI: 10.1002/lt.22395]

45 Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25: 880-885 [PMID: 20074149 DOI: 10.1111/j.1440-1746.2009.06132.x]

46 Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368 [PMID: 18471513 DOI: 10.1053/j.gastro.2008.02.014]

47 von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study. Z Gastroenterol 2009; 47: 21-26 [PMID: 19156588 DOI: 10.1055/s-0028-1109084]

48 Fabrizi F, Aghemo A, Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res 2013; 37: 588-601 [PMID: 24356549 DOI: 10.1159/000355739]

49 Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-158 [PMID: 11981339 DOI: 10.1097/00042737-200202000-00009]

50 Heidemann J, Bartels C, Berssenbrügge C, Schmidt H, Meister T. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract 2015; 2015: 457613 [PMID: 25983746 DOI: 10.1155/2015/457613]

51 Hinz M, Wree A, Jochum C, Bechmann LP, Saner F, Gerbes AL, Gerken G, Canbay A. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol 2013; 12: 92-99 [PMID: 23293199]

52 Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14: 1363-1368 [PMID: 12468959 DOI: 10.1097/00042737-200212000-00013]

53 Rodriguez E, Henrique Pereira G, Solà E, Elia C, Barreto R, Pose E, Colmenero J, Fernandez J, Navasa M, Arroyo V, Ginès P. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transpl 2015; 21: 1347-1354 [PMID: 26178066 DOI: 10.1002/lt.24210]

54 Testro AG, Wongseelashote S, Angus PW, Gow PJ. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 2008; 23: 1535-1540 [PMID: 17784863 DOI: 10.1111/j.1440-1746.2007.05176.x]

55 Tan HK, Marquez M, Wong F, Renner EL. Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. Transplantation 2015; 99: 1441-1446 [PMID: 25643142 DOI: 10.1097/tp.0000000000000557]

56 Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005; 20: 1813-1820 [PMID: 15956066 DOI: 10.1093/ndt/gfh930]

57 Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009; 43: 680-685 [PMID: 19238094 DOI: 10.1097/MCG.0b013e318188947c]

58 Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation 2011; 91: 1141-1147 [PMID: 21544034 DOI: 10.1097/TP.0b013e31821690bf]

59 Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 15-19 [PMID: 11322061]

60 Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505 [PMID: 17560680 DOI: 10.1016/j.jhep.2007.04.010]

61 Nassar Junior AP, Farias AQ, D’ Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014; 9: e107466 [PMID: 25203311 DOI: 10.1371/journal.pone.0107466]

62 Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015; 62: 567-574 [PMID: 25644760 DOI: 10.1002/hep.27709]

63 Caraceni P, Santi L, Mirici F, Montanari G, Bevilacqua V, Pinna AD, Bernardi M. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 2011; 43: 242-245 [PMID: 20833118 DOI: 10.1016/j.dld.2010.08.001]

64 Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-422 [PMID: 9696006 DOI: 10.1002/hep.510280219]

65 Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997; 349: 697-698 [PMID: 9078203 DOI: 10.1016/S0140-6736(97)24010-9]

66 Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-295 [PMID: 10896924 DOI: 10.1136/gut.47.2.288]

67 Berry K, Lerrigo R, Liou IW, Ioannou GN. Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2016; 14: 118-123 [PMID: 26192147 DOI: 10.1016/j.cgh.2015.06.042]

68 Brown RS, Lake JR. Transjugular intrahepatic portosystemic shunt as a form of treatment for portal hypertension: indications and contraindications. Adv Intern Med 1997; 42: 485-504 [PMID: 9048128]

69 Di Campli C, Santoro MC, Gaspari R, Merra G, Zileri Dal Verme L, Zocco MA, Piscaglia AC, Di Gioacchino G, Novi M, Santoliquido A, Flore R, Tondi P, Proietti R, Gasbarrini G, Pola P, Gasbarrini A. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc 2005; 37: 2547-2550 [PMID: 16182739 DOI: 10.1016/j.transproceed.2005.06.048]

70 Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, Schmidt R. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001; 5: 417-422 [PMID: 11778928]

71 Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002; 26: 103-110 [PMID: 11879237 DOI: 10.1046/j.1525-1594.2002.06822.x]

72 Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Löhr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286 [PMID: 10827226 DOI: 10.1002/lt.500060326]

73 Gaspari R, Cavaliere F, Sollazzi L, Perilli V, Melchionda I, Agnes S, Gasbarrini A, Avolio AW. Molecular adsorbent recirculating system (Mars) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs. Transplant Proc 2009; 41: 253-258 [PMID: 19249528 DOI: 10.1016/j.transproceed.2008.10.066]

74 Yang YW, Wu CH, Hu RH, Ho MC, Tsai MK, Wu YM, Lee PH. Longitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary center. Hepatol Int 2010; 4: 507-510 [PMID: 20827408 DOI: 10.1007/s12072-010-9180-8]

75 Sanchez EQ, Gonwa TA, Levy MF, Goldstein RM, Mai ML, Hays SR, Melton LB, Saracino G, Klintmalm GB. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004; 78: 1048-1054 [PMID: 15480173 DOI: 10.1097/01.TP.0000137176. 95730.5B]

76 Goyal S, Dixit VK, Jain AK, Shukla RC, Ghosh J, Kumar V. Intrarenal resistance index (RI) as a predictor of early renal impairment in patients with liver cirrhosis. Trop Gastroenterol 2013; 34: 235-239 [PMID: 25046885]

77 Maddukuri G, Cai CX, Munigala S, Mohammadi F, Zhang Z. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci 2014; 59: 471-481 [PMID: 24146317 DOI: 10.1007/s10620-013-2899-z]

78 Saxena V, Lai JC. Kidney Failure and Liver Allocation: Current Practices and Potential Improvements. Adv Chronic Kidney Dis 2015; 22: 391-398 [PMID: 26311601 DOI: 10.1053/j.ackd. 2015.05.002]

79 Chang Y, Gallon L, Shetty K, Chang Y, Jay C, Levitsky J, Ho B, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI. Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies. Transplantation 2015; 99: 424-430 [PMID: 25099700 DOI: 10.1097/tp.0000000000000270]

80 Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Reddy KR. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005; 11: 1048-1055 [PMID: 16123966 DOI: 10.1002/lt.20445]

81 Jeyarajah DR, Gonwa TA, McBride M, Testa G, Abbasoglu O, Husberg BS, Levy MF, Goldstein RM, Klintmalm GB. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997; 64: 1760-1765 [PMID: 9422417]

82 Fong TL, Khemichian S, Shah T, Hutchinson IV, Cho YW. Combined liver-kidney transplantation is preferable to liver transplant alone for cirrhotic patients with renal failure. Transplantation 2012; 94: 411-416 [PMID: 22805440 DOI: 10.1097/TP.0b013e 3182590d6b]

83 Ruiz R, Kunitake H, Wilkinson AH, Danovitch GM, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, Busuttil RW. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735-741; discussion 741-742 [PMID: 16924080 DOI: 10.1001/archsurg.141.8.735]

84 Locke JE, Warren DS, Singer AL, Segev DL, Simpkins CE, Maley WR, Montgomery RA, Danovitch G, Cameron AM. Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts. Transplantation 2008; 85: 935-942 [PMID: 18408571 DOI: 10.1097/TP.0b013e318168476d]

85 Mehrabi A, Fonouni H, Ayoub E, Rahbari NN, Müller SA, Morath Ch, Seckinger J, Sadeghi M, Golriz M, Esmaeilzadeh M, Hillebrand N, Weitz J, Zeier M, Büchler MW, Schmidt J, Schmied BM. A single center experience of combined liver kidney transplantation. Clin Transplant 2009; 23 Suppl 21: 102-114 [PMID: 19930323 DOI: 10.1111/j.1399-0012.2009.01146.x]

86 Sharma P, Goodrich NP, Zhang M, Guidinger MK, Schaubel DE, Merion RM. Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone. Clin J Am Soc Nephrol 2013; 8: 1135-1142 [PMID: 23449770 DOI: 10.2215/CJN.09600912]

87 Sung RS, Wiseman AC. Simultaneous Liver-Kidney Transplant: Too Many or Just Enough? Adv Chronic Kidney Dis 2015; 22: 399-403 [PMID: 26311602 DOI: 10.1053/j.ackd.2015.06.005]

88 Martin EF, Huang J, Xiang Q, Klein JP, Bajaj J, Saeian K. Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database. Liver Transpl 2012; 18: 914-929 [PMID: 22467623 DOI: 10.1002/lt.23440]

89 Catalano G, Tandoi F, Mazza E, Simonato F, Tognarelli G, Biancone L, Lupo F, Romagnoli R, Salizzoni M. Simultaneous Liver-Kidney Transplantation in Adults: A Single-center Experience Comparing Results With Isolated Liver Transplantation. Transplant Proc 2015; 47: 2156-2158 [PMID: 26361666 DOI: 10.1016/j.transproceed.2014.11.073]

90 Lafayette RA, Paré G, Schmid CH, King AJ, Rohrer RJ, Nasraway SA. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997; 48: 159-164 [PMID: 9342487]

91 Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-365 [PMID: 7871566]

92 Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. Transplantation 1991; 51: 428-430 [PMID: 1994538]

93 Seu P, Wilkinson AH, Shaked A, Busuttil RW. The hepatorenal syndrome in liver transplant recipients. Am Surg 1991; 57: 806-809 [PMID: 1746799]

94 Park I, Moon E, Hwang JA, Yu S, Kim BW, Wang HJ, Shin GT, Kim H. Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations. Transplant Proc 2010; 42: 2563-2566 [PMID: 20832544 DOI: 10.1016/j.transproceed.2010.04.049]

95 Junge G, Schewior LV, Kohler S, Neuhaus R, Langrehr JM, Tullius S, Kahl A, Frei U, Neuhaus P. Acute renal failure after liver transplantation: incidence, etiology, therapy, and outcome. Transplant Proc 2006; 38: 723-724 [PMID: 16647455 DOI: 10.1016/j.transproceed.2006.01.074]

96 López Lago AM, Fernández Villanueva J, García Acuña JM, Paz ES, Vizoso EF, Pérez EV. Evolution of hepatorenal syndrome after orthotopic liver transplantation: comparative analysis with patients who developed acute renal failure in the early postoperative period of liver transplantation. Transplant Proc 2007; 39: 2318-2319 [PMID: 17889176 DOI: 10.1016/j.transproceed.2007.07.070]

97 Sato K, Kawagishi N, Fujimori K, Ohuchi N, Satomi S. Renal function status in liver transplant patients in the first month post-transplant is associated with progressive chronic kidney disease. Hepatol Res 2015; 45: 220-227 [PMID: 24698087 DOI: 10.1111/hepr.12339]

98 Cohen AJ, Stegall MD, Rosen CB, Wiesner RH, Leung N, Kremers WK, Zein NN. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002; 8: 916-921 [PMID: 12360433 DOI: 10.1053/jlts.2002.35668]

99 Longenecker JC, Estrella MM, Segev DL, Atta MG. Patterns of Kidney Function Before and After Orthotopic Liver Transplant: Associations With Length of Hospital Stay, Progression to End-Stage Renal Disease, and Mortality. Transplantation 2015; 99: 2556-2564 [PMID: 25989501 DOI: 10.1097/tp.0000000000000767]

100 Weigand K, Bauer E, Encke J, Schmidt J, Stremmel W, Schwenger V. Prognostic value of standard parameters as predictors for long-term renal replacement therapy after liver transplantation. Nephron Clin Pract 2011; 119: c342-c347 [PMID: 22135794]

101 Sethi A, Estrella MM, Ugarte R, Atta MG. Kidney function and mortality post-liver transplant in the Model for End-Stage Liver Disease era. Int J Nephrol Renovasc Dis 2011; 4: 139-144 [PMID: 22163170 DOI: 10.2147/ijnrd.s24812]

102 Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Rodés J. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-146 [PMID: 14672625]

103 Wong F, Leung W, Al Beshir M, Marquez M, Renner EL. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl 2015; 21: 300-307 [PMID: 25422261 DOI: 10.1002/lt.24049]

104 Ikegami T, Shirabe K, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Maehara Y. The impact of renal replacement therapy before or after living donor liver transplantation. Clin Transplant 2012; 26: 143-148 [PMID: 21447144 DOI: 10.1111/j.1399-0012.2011.01450.x]

105 Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, Abu-Elmagd K, Marsh W, Madariaga J, Mazariegos G, Geller D, Bonham CA, Gayowski T, Cacciarelli T, Fontes P, Starzl TE, Fung JJ. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490-500 [PMID: 10998647]

106 Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002; 8: 91-109 [PMID: 11862584 DOI: 10.1053/jlts.2002.31516]

107 A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 1110-1115 [PMID: 7523946 DOI: 10.1056/nejm199410273311702]

108 Distant DA, Gonwa TA. The kidney in liver transplantation. J Am Soc Nephrol 1993; 4: 129-136 [PMID: 7691205]

109 Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-1939 [PMID: 11773892]

110 de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346 [PMID: 10676738]

111 Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591 [PMID: 11558484]

112 Cicinnati VR, Yu Z, Klein CG, Sotiropoulos GC, Saner F, Malagó M, Frilling A, Gerken G, Broelsch CE, Beckebaum S. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007; 26: 1195-1208 [PMID: 17944734 DOI: 10.1111/j.1365-2036.2007.03466.x]

113 Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-570 [PMID: 9824265]

114 Chava SP, Singh B, Stangou A, Battula N, Bowles M, O’Grady J, Rela M, Heaton ND. Simultaneous combined liver and kidney transplantation: a single center experience. Clin Transplant 2010; 24: E62-E68 [PMID: 20618811 DOI: 10.1111/j.1399-0012.2010.01168.x]
Figure Legends